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ABSTRACT 	  
Epidural fibrosis following spinal surgery is common, and subsequent reoperations are 
more technically challenging with higher complication rates.  A safe and effective therapeutic 
solution to this difficult clinical problem has yet to be realized.  Previous research has 
demonstrated the effectiveness of alanyl-glutamine in reduction of peritoneal adhesions in a rat 
abdominal sepsis model.  I hypothesized that alanyl-glutamine may be similarly efficacious in 
minimizing epidural fibrosis in a rat laminectomy model.    
Rats were randomized into three groups: no surgery, laminectomy/normal saline and 
laminectomy/alanyl-glutamine (1g kg-1).  The surgical groups underwent a lumbar laminectomy 
with instillation of either normal saline or alanyl-glutamine into the peridural space.  Thirty days 
after surgery, the rats were euthanized and the spinal columns prepared for histological 
evaluation.  A blinded veterinary pathologist and a less experienced student independently graded 
the extent and maturity of epidural fibrosis.   
The laminectomy model was an effective model for epidural fibrosis formation.  Rats that 
underwent laminectomy demonstrated significant fibrosis compared to control animals 
(p<0.001).  However, there was no significant difference in histological grade of fibrosis between 
normal saline and alanyl-glutamine treatment groups (p=0.83).  
Based on this study, alanyl-glutamine does not appear to have an effect in reducing 
epidural fibrosis at a histological level.  It is possible that alanyl-glutamine may have an effect 
that is not detectable using this model, in which case further studies with a more sensitive model 
may be indicated.  Resources may be better used elucidating the mechanism by which glutamine 
acts to reduce adhesions in the peritoneal model and further studies exploiting those mechanisms 
can be designed.  
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1. INTRODUCTION 
1.1 Epidural fibrosis following surgery: defining the problem 
The earliest reference to surgical decompression of the spinal canal was described 
by Paulus of Aegineta (625-690 AD).  Further development of surgical techniques halted 
until the advent of antisepsis and anesthesia in the 19th century.  The first laminectomy in 
the United Stated is attributed to Alban Gilpin Smith in 1829.  However, it wasn’t until 
Mixter and Barr presented their surgical findings regarding ruptured discs at the Annual 
Meeting for the New England Surgical Society in 1933, with subsequent publication in 
the New England Journal of Medicine, that lumbar laminectomy and discectomy became 
one of the most common operations performed by neurosurgeons1. 
Case series presenting the results of lumbar spinal decompression surgery began 
to be published in the mid-twentieth century2-5.  In these early reports, up to 19% of 
patients had persistent or recurrent pain.  A small percentage underwent re-exploration 
and the majority was found to have dense fibrotic adhesions in the epidural space.  In 
these early years of spine surgery before the advent of sophisticated imaging techniques, 
one could speculate that significant portions of these failures were due to wrong 
diagnosis and wrong level surgery.  However, despite advances in technology and 
surgical technique, unsatisfactory outcomes following spinal surgery remain a significant 
problem.  Recent literature reviews suggests failure rates of 20-46% for lumbar spine 
surgery, dependent on the nature of the procedure6 7.  Applying these numbers to an 
estimated 28,000 spinal surgeries performed in Canada each year results in an alarming 
number of unsatisfactory results8. 
The term “failed back surgery syndrome (FBSS)” has been coined to describe this 
group of patients – those who have unresolved or new onset of symptoms following 
lumbar spine surgery9, or whose outcome does not meet the pre-surgical expectations of 
the patient and surgeon10.   Rather than a technical failure, the term refers to a failure of 
the treatment to alleviate the preoperative symptoms.  The FBSS population encompasses 
a heterogeneous patient group with varied preoperative diagnoses who have undergone 
different, and sometimes multiple, surgical procedures.  The myriad of surgical and 
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nonsurgical explanations for their symptoms present a diagnostic challenge.  Chan and 
Peng proposed a practical classification that considers etiology of FBSS based on 
preoperative factors (patient factors, procedure selection), intraoperative (technique, 
incorrect level, inability to achieve aim of surgery), and postoperative (progressive 
disease, epidural fibrosis, surgical complication, iatrogenic instability)6.  Of these factors, 
epidural fibrosis has received particular interest as a potentially preventable factor.   
Epidural fibrosis is the expected end result after surgical manipulation of the 
epidural space, and can be defined as scar formation at the site of surgical access into the 
spinal canal, in intimate vicinity to and around the origin of the radicular sheath11. The 
full extent of the epidural fibrosis is realized by six months postoperatively12.  Contrast 
enhanced magnetic resonance imaging (MRI) remains the best confirmatory test for 
epidural fibrosis13, and is often undertaken to investigate alternate explanations for 
ongoing postoperative pain.  The typical appearance is that of a nonspecific enhancing 
soft tissue mass surrounding the nerve roots and thecal sac at the operative level14. The 
extent and severity of fibrosis is not necessarily dependent on the type of procedure, and 
can vary between individuals undergoing the same procedure15-18.   
Recognition of epidural fibrosis as a potential problem has led to significant 
research to characterize the wound healing response and to investigate substances to 
prevent fibrosis and novel treatment modalities.  This effort has been paralleled by 
refinements in surgical technique and advancements in minimally invasive techniques 
that minimize tissue disruption.  Despite the progress that has been made, the rate of 
unsatisfactory outcomes following lumbar spine surgery remains unchanged from that 
reported in the 1950s and there remains a large group of patients who are not helped by 
surgery.  Physicians are ill-equipped to manage this ever-growing population of patients 
with chronic pain, and epidural fibrosis remains a challenge for surgeons performing 
revision procedures. 
  1.1.1 Prevalence 
Modern imaging techniques have facilitated detection and diagnosis of a variety 
of postoperative conditions that may lead to persistent pain following spinal surgery.  
Imaging remains a useful tool to appreciate the extent of a problem within a population 
and gauge response to intervention. 
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In studies of symptomatic postoperative patients, imaging has revealed the 
prevalence of epidural fibrosis in 46-100%16 19-21.  Epiduroscopy in a similar population 
demonstrated significant fibrosis in 91%22.  These numbers are not surprising, as the 
formation of epidural fibrosis is a normal response to any surgical intervention that 
involves manipulation of the epidural space.  Some degree of peridural fibrosis will be 
seen on MRI in the majority of asymptomatic postoperative patients13 15 16 21-25.  What the 
data is unable to define for physicians is what percentage of those affected by epidural 
fibrosis have symptoms that can be attributed to epidural fibrosis.   
1.1.2 The relationship between epidural fibrosis and clinical outcome 
Epidural fibrosis is frequently associated with unsatisfactory clinical outcomes, 
with some authors implicating epidural fibrosis as a causal or contributory factor in 20-
36% of FBSS patients21 26 27.  When pain persists or recurs following surgical 
intervention, contrast enhanced MRI is the diagnostic modality of choice to investigate 
the etiology of the symptoms.  As discussed previously, a significant proportion of post-
operative patients will demonstrate epidural fibrosis on imaging.  When fibrosis is the 
sole finding on subsequent investigations or during revision surgical procedures, some 
surgeons erroneously associate pain with fibrosis.  However, establishing causality 
between fibrosis and clinical outcome demands rigorous investigation that establishes a 
biologic mechanism that explains the association, clinical studies that consistently 
support that association and studies that demonstrate alteration of outcome with treatment 
of fibrosis.  The literature to date fails to adequately address each of these requirements, 
and therefore there remains debate as to whether the presence, location or severity of 
epidural fibrosis contributes to post-operative patient symptomatology. 
The focus of the majority of research conducted to date has focused on prevention 
of fibrosis and treatment of adhesions, with comparatively little effort expended on 
exploring the biologic mechanism by which epidural fibrosis may cause pain.  The 
current hypothesis is that the fibrotic material acts as a mechanical tether of the nerve 
root.  Rather than a direct compressive effect28, it is more likely that fibrosis limits the 
mobility of an already injured and inflamed nerve root and increases susceptibility to 
degenerative stenosis and recurrent herniation29.  Additionally, fibrotic material may 
impair vascular and cerebrospinal fluid flow, resulting in hypoxia and hypersensitivity of 
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the nerve root30 31.  This may explain findings in animals that show increased axonal 
swelling and electrophysiological conduction blocks in fibrotic areas unrelated to a 
preexisting lesion or intraoperative iatrogenic damage28 32.   More research needs to be 
undertaken to expand upon and validate the current hypotheses. 
Clinical studies undertaken to explore the relationship between fibrosis and post-
operative symptoms have been unable to demonstrate an association between presence, 
severity or location of fibrosis and symptomology15-18 24 33.  Several of these studies have 
limitations including small sample size16 24, not defining pain symptoms as radicular15 24 
and premature imaging prior to maturation of fibrosis33.  However, the studies employing 
modern imaging techniques and validated outcome measures fail to demonstrate any 
association between presence or extent of epidural fibrosis and postoperative radicular 
pain17 18.  Of the studies claiming an association between postoperative fibrosis and pain, 
only a single trial examined a suitable sample size and utilized modern imaging 
techniques21.  Ross et al state that patients with fibrosis were 3.2 times more likely than 
patients without fibrosis to develop recurrent radicular pain after discectomy.  However, 
this oft-quoted finding could only be demonstrated on an analysis of a small subgroup, 
and the majority of those affected by severe fibrosis were asymptomatic.  Clinical trials 
have been unable to explain why some patients with epidural fibrosis remain 
asymptomatic while others develop severe pain.   
Revision surgery in the setting of epidural fibrosis as the sole finding is seldom 
undertaken as fibrotic areas paradoxically heal with more scar tissue, and outcomes have 
been poor34-38.  Interventional techniques such as percutaneous and endoscopic 
adhesiolysis (a procedure which mechanically lyses epidural adhesions) have been 
explored as less invasive treatment options for postoperative patients with epidural 
fibrosis and persistent symptoms.  Proponents of the technique claim that high volume 
lavage mechanically lyses adhesions, reduces local concentrations of inflammatory 
mediators and facilitates drug delivery to target areas39.  The sole randomized controlled 
trial that examined a postoperative population of patients with epidural fibrosis 
undergoing percutaneous adhesiolysis versus caudal epidural injection suggests clinically 
significant improvements in both pain and disability scores in the adhesiolysis group40.  
Additionally, a recent systematic review that included trials that looked at more 
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heterogeneous patient populations found fair evidence that adhesiolysis is effective in 
treatment of chronic pain following lumbar surgery41.  However, a biomechanical study 
suggests that forces transmitted by catheter are incapable of releasing fibrotic tissue42.  
Additionally, a recent study with a placebo intervention arm has demonstrated long 
lasting clinically significant reductions in pain and disability scores in patients receiving 
placebo intervention43.  Furthermore, the majority of the literature on the topic has been 
published by a small group of researchers, and has compared patient populations with 
heterogeneous diagnoses utilizing varying treatment protocols.  Adhesiolysis is a novel 
and interesting technique, but has yet to be demonstrated to be an effective treatment 
option for post-operative epidural fibrosis. 
Epidural fibrosis has been implicated as a potential cause of persistent pain 
following surgery, but the relationship remains unclear.  Studies have failed to 
demonstrate a clear biologic mechanism and clinical studies point to lack of an 
association between fibrosis and pain.  Further research is needed to determine whether 
there is any benefit of treatment of adhesions.  In postoperative patients, it is unlikely that 
epidural fibrosis is the sole explanation for persistent pain.  Pain is often multifactorial 
and a myriad of other diagnoses and psychological factors likely contribute to poor 
clinical outcomes. 
  1.1.3 Revision surgery 
The growing aging population has increasing lifestyle expectations, and more 
people are presenting to the spine surgeon.  New surgical techniques have allowed spine 
surgery to become an option for an increasing number of patients, and there has been a 
corresponding rise in surgical rates.  Unfortunately, although safe and effective, current 
less invasive techniques have not resulted in decreased complication or reoperation 
rates44 45.  Studies suggest stable reoperation rates independent of initial diagnosis or 
procedure type46.  Approximately 15% of patients undergoing lumbar surgery will come 
to reoperation within five years, and 21-34% of these will undergo “repeat revision” 
surgery26 47 48.  Of those having one reoperation, approximately one third will require 
multiple repeat revision surgeries26 48.  With increasing number of procedures being 
performed, it is likely that the burden of revision surgery will continue to grow. 
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There are many reasons why an individual may come to require a revision spine 
procedure.  Failure to achieve or maintain improvement after the initial surgical 
procedure may result from progressive neurological deficit or deformity, various 
complications (i.e. pseudarthrosis, infection, cerebrospinal fluid [CSF] leak, implant 
related), persistent or recurrent debilitating pain or a combination of the aforementioned 
factors.  In the first two of these groups, established surgical decision making pathways 
guide management of surgically correctable structural or neurological lesions.  In the 
latter, the broad differential diagnosis of persistent or recurrent pain often combined with 
psychological factors and secondary gain issues, can make diagnosis and management 
challenging.  Therefore, careful evaluation to establish the underlying etiology is 
essential in every case being considered for revision surgery.   
Revision procedures pose additional technical challenges for the spine surgeon.  
Re-exploration in subsequent spinal procedures is more time consuming, technically 
challenging and is associated with higher complication rates49-59.  Dense epidural fibrosis 
alters the natural tissue planes resulting in an increased risk of inadvertent dural injury 
and CSF leak49-52 54-57 59.  Nerve roots that are adherent to fibrotic material are less mobile 
and are more difficult to safely identify and expose, with increased likelihood of direct or 
traction-related injury53 57.  Revision spinal procedures have also been associated with 
significantly increased operative time, blood loss and infection rates52 58 60 61.  While the 
increased complication rate in revision procedures has not been shown to have adverse 
effects on long term patient outcome, prolonged hospitalization and need for additional 
procedures imparts additional financial cost to society52 62 63.  The development of a 
treatment that could reduce or eliminate epidural fibrosis may simplify subsequent 
reoperation and prevent complications, thereby resulting in positive economic 
implications. 
Outcomes of revision procedures are highly dependent on the indication for the 
intervention.  If a structural cause for a patient’s symptoms can be identified and 
corrected with revision surgery, outcomes are generally satisfactory.  Despite often 
requiring more invasive procedures and having higher complication rates, revision 
patients demonstrate equivalent improvements in outcome to patients undergoing a 
primary procedure52 64 65.   This is unfortunately not the case in FBSS patients lacking a 
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structural explanation for their pain.  In cases where a structural lesion is not identified, 
epidural fibrosis is often the sole finding, and reoperation in this setting has disappointing 
results9 35 37 66.  For this reason, experts agree that reoperation in the setting of epidural 
fibrosis as the sole finding is generally contraindicated26 67. 
1.2 Phases of wound healing 
Wound healing is the complex and dynamic process that results in the restoration 
of anatomical continuity and function after an injury68.  Fibrosis is the normal end result 
of the wound healing process, and occurs in the setting of both surgical and traumatic 
wounds.  Wound healing in humans exists on a clinical spectrum, and normal healing 
demands equilibrium between fibroblastic proliferation and remodeling.  Occasionally, 
excess fibroplasia results in pathologic healing in the form of adhesions, keloid scars and 
contractures.  Inadequate healing can also occur, leading to tissue breakdown, dehiscence 
and chronic skin ulceration.  These challenging clinical problems can be difficult to treat 
and are associated with significant morbidity.  Solutions can only be achieved with a 
thorough understanding of the basic mechanisms that underlie the wound healing process. 
The healing process is well studied and involves a complex series of events.  The 
process of acute wound repair differs little from one tissue to another and is generally 
independent of the form of injury69.  Four distinct but overlapping stages have been 
recognized, including hemostasis, inflammation, proliferation and remodeling70. 
1.2.1 Hemostasis 
The initiation of wound healing begins the moment the tissue architecture is 
disrupted.  Blood extravasates into the wound, and platelets come into contact with 
exposed collagen.  This results in platelet degranulation and release of clotting factors 
and cytokines.  Clotting factors allow hemostasis and the formation of a fibrin clot in the 
wound.  Cytokines, including platelet-derived growth factor (PDGF) and transforming 
growth factor-beta (TGF-β), attract inflammatory cells to the wound71.  The fibrin clot 
acts as a scaffold for the migration of inflammatory cells into the wound, and their arrival 
signals the start of the inflammation phase.   
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1.2.2 Inflammation 
The immune response is critical to wound healing, and involves several types of 
cells and many mediators, which act in concert to achieve a successful outcome.  
Neutrophils are the first leukocytes to arrive at the wound and are present within six 
hours, peaking in concentrations at 24-48 hours post-injury72.  They function to 
phagocytize dead cells, bacteria and debris and to release cytokines and chemoattractants 
that encourage infiltration of macrophages.  An unknown stimulus results in apoptosis of 
the neutrophils, and the infiltrating macrophages ingest the neutrophils and take over 
their phagocytic role73. 
Macrophages are derived from circulating monocytes and reach peak 
concentration in the wound at 72 hours post injury69.  In addition to replacing the 
neutrophil as the main phagocytic cell, they also play a critical role in the release of 
cytokines and growth factors to orchestrate the repair process71.  These cytokines recruit 
other cells, including additional macrophages, lymphocyte, and fibroblasts to the wound.  
In the absence of significant contamination the inflammatory phase is very short, lasting 
one to three days after injury74.  However, the modulatory role of macrophages is 
maintained, and they can be detected in the wound after inflammation has ended and until 
the healing process is complete69. 
1.2.3 Proliferation 
T-lymphocytes arrive at the wound approximately one week post-injury and 
signal the transition to the proliferative phase of healing75.  Although essential to wound 
healing, the lymphocytes’ role has not been fully defined76.  In addition to preventing 
infection, they also appear to play a regulatory role.  Lymphocytes exert their various 
influences through the secretion of lymphokines, which have been shown in vitro and in 
vivo to exert both stimulatory and inhibitory effects on fibroblast activity and collagen 
synthesis77.   
The proliferation phase is characterized by the appearance of the fibroblast and 
the formation of granulation tissue in the wound.  Cytokines produced by macrophages 
trigger differentiation of fibroblasts from local mesenchymal cells.  By the third day post-
injury, there is a significant expansion of the fibroblast population, and peak numbers are 
reached by the seventh day78.  Fibroblasts produce metalloproteinases that facilitate their 
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movement and rapidly replace the provisional fibrin network with the extracellular matrix 
(ECM)71.  The ECM is rich in type III collagen, fibronectin and hyaluronic acid, and is 
gradually replaced with type I collagen79 80.  This matrix supports further fibroblast 
migration, angiogenesis and granulation tissue80.  Mechanical stress at the wound and the 
influence of TGF-β induce myofibroblasts to differentiate from fibroblasts, which assists 
with wound contraction and closure of the granulated wound. 
1.2.4 Remodeling 
Reorganization of the provisional collagen network begins almost as soon as it is 
laid down.  Collagen that was previously laid down in a random fashion is reorganized by 
fibroblasts into thick bundles that are cross-linked along the lines of stress in the tissue81 82.  
Fibroblast cells undergo apoptosis and their numbers begin to decrease at approximately 
day 14.  The down regulation the fibroblast population is not completely understood, but 
is of importance in certain clinical scenarios, such as hypertrophic and keloid scarring, 
contractures and chronic non-healing wounds.  Despite a down regulation in fibroblast 
population, collagen synthesis will continue for four to five weeks after injury73.  Wound 
tensile strength is slow to increase, with the scar having achieved 20% of final strength at 
three weeks.  Although scar remodeling continues for months to years after injury, even 
in a mature scar only 80% of tensile strength is ultimately restored83.  Complete 
restoration of normal tissue architecture is never achieved84. 
1.3 Review of literature on previously investigated potential antifibrotic agents 
 Coincident with early reports on failed lumbar surgery and the suggestion that 
epidural fibrosis may play a contributory role, studies began to emerge investigating 
ways to ameliorate epidural fibrosis formation.  After fifty years of research, potential 
treatments can be grouped into two broad categories: natural or synthetic substances that 
aim to act as an interpositional barrier between the neural elements and fibrotic tissue, 
and newer techniques that aim to modulate the immune system and the inflammatory 
response.  Each of these categories has had contenders that demonstrate limited success, 
but all have failed to make the leap to more widespread clinical use. 
 The very first studies concentrated on the initial stages in the wound healing 
process – the extravasation of blood into the surgical bed, and the migration of 
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fibroblasts.  Although little was understood about the wound healing process at the time, 
it was generally accepted that fibrotic tissue forms as a result of fibroblast migration from 
posterior tissues (paraspinal muscles, ligamentum flavum, posterior longitudinal 
ligament)85 86.  The focus of this early research was on materials that could act as a 
physical barrier between the migrating fibroblasts and the neural structures.   
 Researchers recognized that the intimate relationship between any barrier substance 
and surrounding neural structures would necessitate that substance to be inert, non-
immunogenic and non-toxic.  Ideally, it would also be easy to place at the time of 
procedure, and result in little to no patient morbidity.  Meeting these criteria, and one of 
the first interpositional materials to be investigated, was autogenous fat graft.  The 
mechanism by which free fat graft alters the formation of fibrosis has not been 
established.  Theoretically, the fat graft occupies the operative space to act as a physical 
barrier against hematoma and fibroblasts87.  Initial success at reducing fibrosis in animal 
models has not been consistently reproduced in human studies, and it is unlikely that fat 
grafting has any effect on clinical outcomes88.  Subsequent reports on graft migration 
resulting in cauda equina syndrome or nerve root compression and questions about 
efficacy have led to a decline in clinical use89-93.   
 Research efforts continued to focus on interpositional barrier materials for the 
remainder of the 20th century.  Numerous other synthetic interpositional materials were 
investigated, including hemostatic agents94 95, silastic membranes96, sodium 
hyaluronate97, synthetic polymers98-101, carboxymethylcellulose102 and bioabsorbable 
antifibrotic gels103 104.  Of these, only carboxymethylcellulose gel and 
polytetraflouroethylene (GoreTexTM) have demonstrated positive results in animal studies 
and have been proven non-toxic in human trials105-107.  High quality human trials 
demonstrating objective evidence of a decrease in fibrosis with clinically significant 
differences in outcomes are lacking. 
 Over the last fifteen years an improved understanding of the wound healing process 
has resulted in a shift in research focus to agents that modulate the immune system, the 
inflammatory response and fibroblast proliferation.  Corticosteroids108, mitomycin C109-112, 
hydroxycamptothecin113, colchicine114, tissue plasminogen activator115, methylene 
blue116, azithromycin117, human amniotic membrane118 119, all-trans retinoic acid120, 
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verapamil121, bevacizuman and 5-flourouracil122 have been investigated.  Of these, 
mitomycin C and hydroxycamptothecin have had promising anti-fibrotic effects, but 
predictably, further development has been hindered by problems with wound healing123 124.  
The inflammatory cascade plays an intricate role in wound healing, and the ability to 
target powerful immunomodulators to just the ‘undesirable fibrosis’ whilst preserving 
normal wound healing remains a hurdle to be overcome. 
Research on epidural fibrosis has progressed significantly from initial studies 
investigating autologous fat grafts.  Despite intensive research effort, inconsistent results 
in animal models and concerns about local toxicity and wound healing have not 
translated into clinical success, and no single agent is currently routinely used to decrease 
epidural fibrosis following spinal surgery. 
1.4 Glutamine  
1.4.1 Synthesis and metabolism 
Glutamine is the most abundant free amino acid in the plasma125 126.  Although 
orally ingested glutamine is readily taken up at the jejunum, the majority is metabolized 
in the intestine itself by the enterocytes and gut associated immune cells127 128.  The liver 
catabolizes the remainder with conversion to glycogen or glucose129.  The majority of the 
abundant plasma stores are acquired by de novo synthesis at the skeletal muscle130, where 
glutamine alone accounts for greater than 60% of the free amino acid pool131. 
Glutamine synthesis and release are precisely regulated.  In response to 
heightened catabolism, glucocorticoid mediated upregulation of the glutamine synthetase 
gene results in increased formation of glutamine from glutamate and ammonia132. 
Branched-chain amino acids originating from the breakdown of muscle protein, and 
glutamate acquired from the circulation are metabolized in muscle for glutamine 
synthesis128 133.  An amino group is donated to α-ketoglutarate to form glutamate and a 
branched chain α-keto acid.  Glutamine synthetase then catalyzes the formation of 
glutamine from glutamate and ammonia133.  The glutamine synthetase enzyme is most 
abundant in muscle, lung, and adipose tissue, and these form the primary sites of 
glutamine production129.  Based on mass, skeletal muscle is the most significant site of 
production.   
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The ability to be synthesized de novo resulted in glutamine being traditionally 
classified as a ‘nonessential’ amino acid.  However, during catabolic states glutamine 
stores are rapidly depleted, and consumption exceeds synthesis.  During these periods of 
physiologic stress, there is a corresponding release of glutamine into the bloodstream133 134.  
Despite this significant release, glutamine depletion has been demonstrated in catabolic 
states such as critical illness135 136, major trauma137-139, sepsis140 141 and postoperatively142-
144.  The recognition that de novo synthesis is insufficient to meet increased demands in 
certain clinical states has led to a change in nomenclature and glutamine is now 
considered a ‘conditionally essential’ amino acid in states of critical illness or injury76.   
1.4.2 Metabolism and mechanisms of action 
The critical role of glutamine in cell survival and proliferation was first 
demonstrated in vitro in the 1950s.  Experiments in mouse fibroblast and HeLa cell 
culture demonstrated that glutamine had to be present 10- to 100-fold in excess of other 
amino acids in culture, and could not be adequately replaced by glutamic acid or 
glucose145.  It is now known that glutamine is a precursor or product in multiple 
metabolic pathways in a variety of cells and tissues within the body, including the small 
intestine, liver, kidney, immune system and brain.  In addition to this metabolic role, 
glutamine also plays a critical role in the endogenous response to stress.  Decades after 
the importance of glutamine was first recognized, researchers are only beginning to fully 
appreciate the importance of this nutrient at a cellular and whole-organism level.  
Plasma glutamine homeostasis reflects a balance between release from muscle 
and uptake by the splanchnic bed (intestine and liver).  Most of the glutamine produced 
by muscle and released into bloodstream is extracted by the intestine146 147.  Glutamine is 
transported to the mitochondria of the crypt cells of the small bowel, where glutaminase 
converts it to glutamate and ammonia146.  The glutamine is then metabolized to α-
ketoglutarate to be used in the tricarboxylic acid cycle as fuel for the enterocytes and the 
gut associated lymphoid cells148.  The ammonia that is generated during this process is 
excreted as urea, and so glutamine additionally serves as an important shuttle to dispose 
of ammonia from the body.   
The function of the intestine as a major hub in inter-organ glutamine trafficking is 
not accidental, as the intestine itself is a major glutamine utilizer.  The intestinal lumen 
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and the mesenteric arterial circulation serve as dual sources to meet intestinal glutamine 
needs.  A significant proportion of glutamine is oxidized as metabolic fuel for the 
enterocytes and gut associated lymphoid cells148.  Additionally, glutamine serves as a 
precursor for N-acetylglucosamine and N-acetylgalactosamine, which are involved in 
intestinal mucin synthesis and intestinal barrier function148.  Animal models fail to 
develop normal gut integrity in glutamine-deplete environments149, while those 
supplemented with glutamine demonstrate decreased permeability and improved mucosal 
integrity150-154, underscoring the critical role of glutamine in maintenance of intestinal 
structure and function. 
The liver receives the majority of its glutamine supply from the intestine via the 
portal vein155.  The liver is unique in that it has zonally localized glutamine synthetase 
and glutaminase enzymes and is therefore capable of net glutamine uptake or output.  In 
addition to precisely regulating glutamine homeostasis, the zonally localized enzymes act 
simultaneously in an eloquent system capable of removing all excess ammonia from the 
circulation155 156.  The portal blood first contacts the hepatocytes capable of urea 
synthesis, and any ammonia that escapes urea synthesis is subsequently taken up 
downstream for glutamine synthesis156.  During times of low glutamine availability (i.e. 
acidosis following critical illness or injury), glutaminase activity is decreased, and the 
glutamine synthetase activity is increased resulting in net glutamine output.  By utilizing 
glutamine synthesis as a secondary system for ammonia detoxification, this unique 
system ensures systemic ammonia homeostasis. 
Renal glutamine metabolism has a fundamental role in maintaining acid-base 
homeostasis within the body.  Under physiologic acid base conditions, the kidneys extract 
and catabolize very little plasma glutamine129.  The glutamine that is reabsorbed at the 
epithelial cells of the proximal convoluted tubule is metabolized by the 
glutaminase/glutamate dehydrogenase system, with the majority of the generated 
ammonia released to the bloodstream via the renal vein.  A small portion (<30%) is 
excreted in the urine157 158.  In this case, a hydrogen ion dissociated from carbonic acid 
combines with ammonia and is excreted.  The remaining bicarbonate subsequently enters 
the circulation where it plays critical role in acid base balance159.  During periods of 
metabolic acidosis, rising plasma glutamine levels result in increased renal glutamine 
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uptake.  A shift occurs to favor urinary excretion of ammonium, which assists with 
maintenance of acid-base balance158.  The glutamate that was created by the action of 
glutaminase ultimately participates in gluconeogenesis.  Glutamine is the preferred 
gluconeogenic substrate for the kidney, and results in approximately 20% of endogenous 
glucose release to the circulation160. 
Cells of the immune system, including lymphocytes, macrophages and 
neutrophils have high levels of glutaminase and consequently utilize glutamine at a high 
rate161-163.  However, glutamine’s role extends beyond that of a fuel source, and the more 
specific involvement of glutamine in immune system function has only become known 
relatively recently.  Glutamine is involved early and facilitates one of the earliest steps in 
the response to inflammation and infection – migration of immune cells and immune cell 
adhesion to the vascular endothelium at the site of inflammation164.  After the arrival of 
the neutrophil, glutamine appears to enhance phagocytosis and production of reactive 
oxygen species, both of which are required for bacterial killing165 166.  As the 
macrophages arrive, glutamine has a similar role, enhancing phagocytic activity167-169.  
Additionally, glutamine modulates macrophage cytokine release necessary for 
lymphocyte migration, as well as facilitation of antigen presentation to T-lymphocytes170-
172.  Activated T cells begin proliferating, utilizing the familiar glutaminase/glutamate 
dehydrogenase pathway to shuttle α-ketoglutarate into the tricarboxylic acid cycle to 
generate fuel.  Additionally, they convert glutamine to purine and pyrimidines for DNA 
and RNA synthesis173.  The proliferation and differentiation of β-cells is less well studied, 
but also appears to be glutamine dependent174.  
In addition to its role in metabolic function of multiple organs and the immune 
response, glutamine also plays an important role in the endogenous stress response.  
Under physiologic conditions, metabolically active cells are constantly generating and are 
exposed reactive oxygen and nitrogen species175.  This is magnified following critical 
illness or injury, and overwhelms the cellular antioxidant capacity176.  These reactive 
species may interact with proteins, lipids and nucleic acids to disrupt their integrity and 
function177.  The most important intracellular antioxidant response is the glutathione 
system, which eliminates these radicals via reduction178.  Glutamine’s role in this system 
is as a precursor for glutamate, which is required for glutathione synthesis.  An additional 
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family of proteins, the heat shock proteins, specifically assist with protein renaturation 
and degradation176.  They also appear to decrease plasma concentration of 
proinflammatory cytokines179.  Enhanced heat shock protein expression has been shown 
to be cytoprotective in a wide variety of experimental injury models, and glutamine has 
been demonstrated to be a potent enhancer in multiple organs and cell types179.  The 
mechanism by which glutamine enhances heat shock protein remains unknown179. 
In addition to the pathways discussed above, significant glutamine metabolism 
occurs in the brain.  Glutamine is the precursor of the neurotransmitters glutamate and γ-
aminobutyric acid, provides substrates for energy production in the tricarboxylic acid 
pathway and also has a critical role in cerebral ammonia homeostasis180.  While 
important, these pathways have negligible effect on the response to injury or the post-
surgical healing response, and will not be discussed in detail. 
1.4.3 Current clinical applications 
A significant body of basic science research provides many possible mechanisms 
by which glutamine supplementation may exert beneficial effects on multiple organ 
systems.  Growing appreciation for glutamine’s pivotal metabolic role led to 
experimental application in a variety of patient populations with challenging nutritional 
needs.  The most encouraging results have been in the critical illness and oncology 
populations, leading to clinical adoption of specialized nutritional programs.   
A large number of investigations have focused on the clinical efficacy of enteral 
or parenteral glutamine supplementation following critical illness, major surgery or 
injury.  Common to each of these conditions is an increase in glutamine consumption to 
support immune function, protein synthesis, gluconeogenesis, acid-base balance and 
antioxidant status.  In order to meet these demands, catabolism of the skeletal muscle 
protein occurs, with transport of the amino acids to the visceral organs and wound site181.  
Continued glutamine consumption results in sustained glutamine depletion in many 
patients following critical illness or injury136 182.  This deficiency has been associated 
with increased mortality in the critical care population135 183.  Investigators hypothesize 
that exogenous glutamine supplementation would limit muscle wasting, optimize 
metabolic and immune functions and improve patient outcomes. 
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The potential benefit of glutamine supplementation to the critical care population 
has resulted in multiple randomized controlled trials on the subject.  Meta-analyses of 
these trials suggest modest effects on reduction of infection and hospital length of stay, 
but remain divided with respect to the existence of a mortality benefit184-188. It is 
concerning, however, that a recent large multicenter trial reported the converse, 
suggesting increased mortality rates in absence of any observed clinical benefit in 
glutamine supplemented patients critically ill patients with multi-organ failure189 190.  
Analysis of the conflicting data highlights the heterogeneity in study populations, dosing 
regimes and method of administration.  Current Canadian critical care guidelines reflect 
this, and the previous strong recommendation for glutamine supplementation has recently 
been downgraded to one which ‘should be considered’ when parenteral nutrition is 
prescribed to the critically ill191. 
The reported benefits of glutamine supplementation in the critically ill prompted 
interest in application in oncology populations, where adequate nutritional support is 
linked to quality of life and outcomes192-194.  As the body attempts to repair damage 
induced by cytotoxic treatments on rapidly dividing cells, including those of the immune 
system and gastrointestinal tract, increased glutamine demand rapidly outstrips supply.  
Similar to the critical care population, the body attempts to augment circulating 
glutamine through skeletal muscle breakdown, contributing to cachexia.  Despite this, 
glutamine depletion develops over time, with corresponding negative effects on 
glutamine dependent tissues, resulting in loss of gut barrier integrity, immune system 
dysfunction, loss of adipose tissue, increased hepatic production of acute phase proteins 
and insulin resistance195. 
Despite the potential beneficial of glutamine, there was initial reluctance to 
experiment with supplementation in this patient population.  It is known that tumor cells 
preferentially consume glutamine to supply metabolic pathways that support growth and 
proliferation, inducing a net flux from host to the growing malignancy195.  Additionally, 
higher glutathione levels in tumor cells mediate resistance to chemotherapy and 
radiation196 197.  The overriding concern was that glutamine supplementation might 
stimulate tumor growth and enhance the action of glutathione to convey resistance.   
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Fortunately, these concerns have not been realized in vivo.  Multiple studies have 
failed to show stimulation of tumor growth, and evidence in fact supports a glutamine-
mediated decrease in tumor growth198-201.  In patients undergoing conventional 
chemotherapy and radiotherapy, glutamine supplementation has been shown to mitigate 
side effects associated with cytotoxicity202-208, improve immune cell counts209 210 and 
sustain gastrointestinal barrier function209 211-214.  Potential benefit has also been observed 
in bone marrow transplant populations with meta-analysis suggesting that glutamine 
supplemented patients have lower incidence of mucositis, graft versus host disease and 
infectious complications215.  Again, relative small numbers of studies with considerable 
heterogeneity in study populations, dosing regimes and methods of administration limits 
clinical applicability.  
A growing body of clinical evidence suggests a beneficial role for glutamine 
supplementation in the critically ill and oncology populations.  However, further clinical 
trials are needed to determine which sub-populations benefit the most, and the optimal 
dosing regime and duration.  Until then, strong clinical guidelines will remain lacking, 
leaving the clinician to weigh the evidence for each unique clinical situation. 
1.4.4 Potential role in wound healing 
Surgical intervention results in an inflammatory response with increased 
catabolism and transport of energy, free fatty acids and amino acids to the wounded site 
and a corresponding fall in plasma glutamine levels181 216 217.  Adequate post-operative 
nourishment is essential to support this response, resulting in a cosmetically acceptable 
wound with maximal mechanical strength with minimal disruption of tissue architecture 
and maintenance of tissue planes.  Given glutamine’s critical involvement with the 
metabolism of cells involved with wound repair, it is reasonable to hypothesize that 
supplementation to normalize plasma glutamine levels would optimize metabolic 
conditions for healing. 
Animal studies provide a significant amount of indirect evidence of a positive 
effect of glutamine supplementation on post-operative wound healing.  Several studies of 
enteral glutamine supplementation in a colonic anastomosis model demonstrate enhanced 
angiogenesis, inflammatory and fibroblast cell counts and collagen deposition with 
resultant increase in mechanical strength of the anastomosis site218 219.  The intestinal 
	   18	  
healing environment, however, is unlike that of a surgical wound, and effects of enteral 
glutamine may be due to trophic effects on locally responsive intestinal cells.  However, 
the effects are not merely trophic as positive effects on anastomotic healing can still be 
demonstrated after parenteral administration220. 
Studies investigating glutamine supplementation in cutaneous models of healing 
have revealed mixed results.  Incisional healing models demonstrate increased collagen 
deposition and tensile strength221 222, and an excisional model revealed increased 
angiogenesis, macrophage and fibroblast infiltration and collagen deposition with 
resultant decreased time to wound healing222.  Two other studies utilizing the excisional 
model failed to show an effect of glutamine supplementation, however the treatment dose 
was significantly lower than in other studies223 224. 
The majority of clinical trials investigating the effect of glutamine 
supplementation in surgical populations have focused on broader clinically important 
outcomes (ventilator time, hospital stay, rates of infection, mortality).  A recent meta-
analysis revealed positive effects of parenteral glutamine supplementation on reduction of 
infection related complications and length of stay187.  Although a reduction in infection 
related complications might be related to superior wound healing, there are no studies 
specifically examining the effect of glutamine supplementation on wound healing in a 
surgical population.  Similarly, there are no studies examining specifically a spine 
surgery population, however experts agree that glutamine supplementation may benefit 
all postoperative groups at high risk for infection217. 
Although the metabolic effects of glutamine are well described, the exact 
mechanism by which supplementation affects wound healing remains unknown.  Authors 
who have observed positive effects hypothesize enhanced substrate availability for 
rapidly dividing cells, improved immune cell function and a heightened inflammatory 
response76 218 225.  However, while a robust inflammatory response may be evolutionarily 
desirable for healing of contaminated wounds, there is some evidence suggesting that a 
blunted inflammatory response may result in more desirable healing in controlled 
situations (i.e. non-contaminated surgical wounds).  Studies suggest enhanced, and even 
scarless healing, in mouse lines devoid of inflammatory cells72.  Additionally, mice with 
a deletion of the gene responsible for the SMAD family of proteins that mediate TGF-β 
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signaling and inflammatory cell activation demonstrate reduced influx of inflammatory 
cells and accelerated cutaneous wound healing226.  This is consistent with research in 
fetal healing, which has minimal or no scar formation prior to 24 weeks gestation227.  
Fetal wounds demonstrate an attenuated inflammatory response228-230, and there is a 
positive correlation between increased inflammatory cell activity in older fetuses and 
increased scarring231.  If a blunted inflammatory response results in superior wound 
healing, then perhaps the effect of glutamine supplementation is antagonistic to healing 
with minimal scar, instead supporting exuberant collagenization at the wound site.   
Post-operative glutamine supplementation has beneficial effects on clinically 
important outcomes, but strong evidence supporting a direct benefit to wound healing is 
lacking.   Further research need to be undertaken to characterize the optimal healing 
environment required to achieve maximal wound mechanical strength with minimal 
tissue disruption, recognizing that the ideal environment might be unique to each clinical 
situation.  Only with the knowledge of the mechanisms underlying the optimal healing 
response can research be undertaken to attempt to modulate that response with targeted 
supplementation of key nutrients or factors. 
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2. HYPOTHESIS AND RESEARCH OBJECTIVES 	  
Given the critical role of glutamine in the body’s response to trauma and wound 
healing pathways, and its effectiveness in reduction of peritoneal adhesions in a rat 
abdominal sepsis model232, it is reasonable to hypothesize that glutamine may be 
similarly efficacious in reducing fibrosis in other clinically relevant areas.  This study 
tests the hypothesis that peridural application of glutamine will result in decreased 
formation of epidural fibrosis in rats following laminectomy.  The precise mechanism of 
glutamine’s effect is unknown, but is presumed to be through local modulation of the 
cells involved in wound healing.   
To test this hypothesis, the research objectives were: 
1. To determine whether there is any significant difference between histological extent 
and maturity of epidural fibrosis in rats having undergone laminectomy and instillation of 
normal saline versus those who were treated with alanyl-glutamine. 
2. To determine whether there are any adverse effects of peridural alanyl-glutamine 
application on the animal or the healing wound. 
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3. MATERIALS AND METHODS 
3.1 The animal model 
Peridural fibrosis has been consistently produced in rats, rabbits and dogs85 87 233 
234.  The course of fibrosis development following laminectomy in the rat is similar to 
that observed in other animal models233.  However, when compared to other models, the 
use of the rat model is advantageous with respect to its relative low cost, ease of 
availability and care.  
In this study, the animals were followed for a period of 30 days following 
treatment prior to euthanasia and tissue preparation.  This allows adequate time to 
observe the animal for any adverse effects of the treatment substance, monitor wound 
healing and allow for fibrosis formation.  In the rat model, fibrosis at the laminectomy 
site is evident as early as 15 days.  Beyond 30 days, new bone may form over the 
laminectomy defect, making it more difficult to identify during tissue harvest233. 
3.2 Animal preparation 
All care and treatment protocols were approved by the University of 
Saskatchewan Animal Care Committee prior to experimentation.  Animals were treated 
in accordance with the Canadian Council on Animal Care Guidelines. 
Adult male Wistar rats (Charles River, Laval, PQ, Canada) were acclimatized for 
one week prior to surgery.  Rats received standard rat chow and water ad libitum and 
were kept in a 12:12 hour light-dark cycle at 25° Celsius.   
Anesthesia was induced with inhalational isoflurane 2% (MTC Pharmaceuticals, 
Cambridge, ON, Canada) in oxygen at 5 liters min-1.  Animals were maintained under 
anesthesia using inhalational isoflurane 2% at 2-3 liters min-1.  Preoperative analgesia 
was provided with subcutaneous buprenorphine 0.05 mg kg-1 (Western Drug Distribution 
Center, Edmonton, AB, Canada).  Each rat was marked with an identifying ear tag.  The 
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rat was placed in the prone position, and the dorsal skin overlying the operative site was 
shaved and sterilized with Hibitane® (chlorhexidine gluconate, Ayerst Laboratories, 
Montreal, ON, Canada) and 70% ethanol.  
3.3 Groups and treatments 
Rats were randomized into two groups (Table 1): a surgical control group who 
underwent laminectomy with instillation of normal saline (n=34), and a treatment group 
that underwent laminectomy with alanyl-glutamine instillation 1g kg-1 (n=36).  Dose was 
selected based on previous research232 235 236, and approached the maximal soluble 
concentration237.  A weight-based calculation was performed to determine the volume of 
alanyl-glutamine 400 mg ml-1 (AdeTherapeutics Inc., Saskatoon, SK, Canada) to be 
instilled to achieve a dose of alanyl-glutamine 1 g kg-1.  This was performed for all rats, 
therefore rats receiving normal saline received equivalent volumes.  In addition, 6 
animals underwent no procedure and were used as histological controls.   
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Table 1.1: Treatment groups. 	  





(1 g kg-1) 
Total 6 34 36 
 
3.4 Surgical procedure 
Standard sterile surgical techniques were used.  Using anatomic landmarks, a 
dorsal midline incision was made from the fifth lumbar vertebra (L5) to the second sacral 
vertebra (S2).  The paraspinal muscles were bluntly dissected away from the spinous 
processes and retracted. Using a dissecting microscope and rongeur, a bilateral total 
laminectomy of a lumbosacral vertebra was completed laterally to the level of the 
pedicle.  The ligamentum flavum (the elastic ligament that connects adjacent vertebrae) 
and epidural fat were removed to expose the dura mater (the outermost membrane 
enveloping the spinal cord).  Throughout the procedure, hemostasis was maintained by 
irrigation with saline and compression with surgical pads.  Bipolar cautery, bone wax or 
other hemostatic agents were not used. 
The treatment substance was instilled into the laminectomy site just prior to 
wound closure.  In all groups, fascia at the laminectomy site was marked with a non-
absorbable suture to facilitate harvest of pathological specimens.  Wounds were closed by 
approximating the paraspinal muscles, fascia and subcutaneous tissues using 3-0 Vicryl® 
absorbable sutures. The skin was closed using staples. The rat received 2 mL of lactated 
Ringers solution subcutaneously to restore lost bodily fluids.  Post-operative analgesia 
involved a tapering dose of subcutaneous buprenorphine every 12 hours for three days.   
No prophylactic antibiotics were used.  The rats were observed for postoperative 
complications, and were monitored daily for signs of sensory deficit distal to the 
laminectomy site.  Sutures were removed seven days following surgery. 
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3.5 General necropsy and tissue harvest 
Animals were killed 30 days after surgery under general anesthesia (1.5-2% 
isoflurane in oxygen with a flow rate of 1.5 liters min-1).  Within two hours of euthanasia, 
the rats underwent necropsy and the major organ systems were examined 
macroscopically.  The lumbosacral portion of the spinal column was removed en bloc and 
fixed in 10% neutral buffered formalin for 7 days while on a shaker at 60 rotations per 
minute (rpm).  This was followed by slow decalcification process in 20% formic acid for 
84 hours, also on a shaker at 60 rpm.	  
3.6 Tissue preparation 
The surgical laminectomy site was identified, and three blocks were trimmed: one 
section at the marked site of laminectomy, and two sections 2.5 mm cranial and caudal to 
the marked site (Figure 1).  The trimmed blocks were sectioned (5 micron[µm] thick) and 
stained with Masson trichrome technique. 
  





Figure 3.1: Sectioning technique.   
Sections were taken 2.5 mm cephalad and caudad to the laminectomy site, marked by a 
nonabsorbable suture. 
 
3.7  Histology	  
3.7.1 Masson Trichrome staining 
All sections were stained with Masson trichrome technique238.  This technique 
involves sequential exposure of the tissue sample to stains with varied molecular size, 
resulting in differential take up of the stains by tissue components that have variable 
permeability239.  This results in nuclei staining blue-black, muscle and cytoplasm pink-
red, and connective tissue blue.  Masson trichrome technique is particularly useful for 
differentiation of collagen, and therefore fibrosis, with immature collagen staining a paler 
blue in contrast to darkly stained mature fibers.	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3.7.2 Hematoxylin & Eosin staining of selected specimens 
After Masson Trichrome staining, several samples that appeared to be affected by 
processes that may independently result in fibrosis (i.e. foreign body, pyogranulomatous 
inflammation, hematoma) were identified.  To further characterize these processes, 
subsequent sections were stained with hematoxylin and eosin and examined with regular 
and polarized light. 
  Sections were stained using Harris hematoxylin and eosin238, which results in 
hematoxylin staining nuclear elements and chromatin blue, and eosin staining the 
connective tissue and cytoplasm pink-red. 
3.8 Analysis of histological preparations 
Each section was examined under a light microscope (Olympus 2X and 4X/0.10 
objective, 20X and 40X total magnification). Two digital microphotographs (12.5X and 
20X magnification) were taken for each slide.  Each section was independently evaluated 
at two time points by two raters: an anatomic veterinary pathologist and the author.  The 
treatment from which the histological sections originated was unknown to both of the 
evaluators so as to avoid bias in analysis.  Images presented in this text are representative 
sections reflecting the whole dataset. 
 
3.8.1 Grading of specimens 
The sections were graded on a subjective scale evaluating extent and maturity of 
epidural fibrosis (Figure 2).  Grade 0 represented no fibrosis; Grade 1 represented 
minimal, immature fibrosis; Grade 2 represented moderate fibrosis with mixed immature 
and mature areas; Grade 3 represented dense, mature fibrosis covering the majority of the 
laminectomy defect; Grade 4 represented dense, mature fibrosis occasionally disrupting 
tissue architecture.  The grading scheme was a modified scheme based on that formulated 
by He et al233. 
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Figure 3.2: Histological grading scheme.   
Semi-quantitative evaluation of epidural fibrosis following lumbosacral laminectomy.   
(A) Grade = 0 (control rat); (B) Grade = 2; (C) Grade = 3; (D) Grade = 4.  Masson's 
trichrome stain, 20X magnification. 	  
3.9 Statistical analysis 
 IBM SPSS Statistics software version 22.0 (IBM Corp., Armonk, N.Y., USA) was 
used for statistical analysis. Of the three sections obtained for each animal, the grade at 
the section demonstrating a complete laminectomy was used for statistical analysis.  If 
there was a discrepancy in the grade assigned at the site of complete laminectomy for the 
first and second pathological readings for an animal, the higher grade was used.  Fisher’s 
exact test was used to compare the grade of epidural fibrosis between the treatment 
groups.  The level of statistical significance was defined as p<0.05. 
 The intra-rater reliability was assessed by calculating Cohen’s unweighted kappa 
A	   B	  
C	   D	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value using 104 pairs of independent observations performed by two raters in 52 rats.  
The inter-rater reliability was assessed by calculating Cohen’s unweighted kappa value 
using 104 pairs of observations performed by two raters in 52 animals, comparing scoring 
for first grading of each section.   
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4. RESULTS 
4.1 Surgical time 
The mean operative time across all treatment groups was 25.4 ± 9.4 minutes.  The 
mean operative time in the normal saline treatment group was 26.2 ± 10.6 minutes, and in 
the alanyl-glutamine treatment group 25.6 ± 7.9 minutes (Figure 4.1).  There was a 
statistically significant difference in the mean operative time of the first 50% of 




Figure 4.1: Mean operative time within treatment groups.   
Data expressed as mean, error bars represent ± standard deviation. 
4.2 Intraoperative complications 
There were no intraoperative deaths.   
There were five intraoperative dural breeches (two in the surgical control group 
and three in the alanyl-glutamine group), and three intraoperative nerve root injuries (one 
in the surgical control group and two in the alanyl-glutamine group).  
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4.3 Postoperative complications 
There were two postoperative deaths.  One (in the surgical control group) 
occurred on the third postoperative day, and was likely related to postoperative 
hemorrhage.  The second (in the alanyl-glutamine group) occurred on the sixth 
postoperative day and was unexplained. 
One animal in the treatment group had an unexplained seizure within 6 hours of 
the procedure.  The animal subsequently fully recovered without further intervention.  
This animal was later excluded from histological analysis for reasons unrelated to the 
seizure (unable to identify laminectomy site on histological preparation).  
There were 15 cases of neurologic deficit, manifested by tail numbness.  Eight of 
these cases were in the surgical control group, and 7 were in the alanyl-glutamine group.  
Seven cases were transient.  Eight cases (five in the surgical control group and three in 
the treatment group) had not resolved prior to euthanasia. 
There were fourteen wound hematoma/hygromas (8 in surgical control group and 
6 in alanyl-glutamine group).  Four (2 in surgical control and 2 in alanyl-glutamine 
group) clinically resolved prior to euthanasia.  At the time of necropsy, those that had not 
resolved were found to be organized hematomas or sterile hygromas. 
There were no cases of wound infection. 
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Figure 4.2: Intraoperative and postoperative complications. 	  
4.4 Histological evaluation 
4.4.1 Qualitative observations 
Based on gross evaluation at necropsy, all rats were healthy, with the exception of 
one in the alanyl-glutamine group that had uroliths in the urinary bladder and bilateral 
hydronephrosis.  This was likely an incidental finding and would be unlikely to affect the 
experimental result, however this rat was subsequently excluded from further analysis 
due to other reasons (see discussion below). 
4.4.2 Animals excluded from histological analysis 
Upon histological examination, several rats were affected by processes (i.e. 
pyogranulomatous inflammation associated with foreign material, or adjacent 
hematoma/hygroma), which may independently result in fibrosis indistinguishable from 
that induced by surgery (Figure 4.3).  These processes were further evaluated with 
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the effects of therapeutic anti-fibrotic agents, and therefore these animals (nine in the 
control group and 10 in the alanyl-glutamine group) were excluded from further analysis 
(Figure 4.4).   
Additionally, one rat in the alanyl-glutamine treatment group was excluded from 
further analysis because despite multiple sections, the area of laminectomy site was 
unable to be identified (lamina was intact on all sections).  This was likely due to 
migration of the marking suture during antemortem postsurgical fibrosis or post mortem 





Figure 4.3: Tissue section demonstrating pyogranulomatous inflammation induced 
by foreign material.  
Hematoxylin and eosin stained section exposed to polarized light demonstrating 
pyogranulomatous inflammation induced by foreign material.  Foci of degenerative 




















Figure 4.4: Rats excluded from statistical analysis of grade of fibrosis. 	   	  








Other causes for fibrosis 
evident in histology: 
     Foreign body granuloma (4) 
     Hematoma (4)  
Death (1) 
Unable to identify 









Other causes for fibrosis evident 
in histology: 
     Pyogranulomatous       
     inflammation (2) 
     Foreign body granuloma (5)  
     Hygroma (1) 
Death (1) 	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4.4.3 Comparison of nonsurgical control and animals having undergone laminectomy 
Nonsurgical control rats demonstrated no fibrosis (Figure 4.5).  These served as a 
histological control and a representation of normal tissue architecture and anatomy.   
Rats that underwent laminectomy with instillation of normal saline demonstrated 
exuberant fibrosis in the epidural, deep and superficial epaxial layers.  Fibroblastic tissue 
formed over the laminectomy defect, and extended to adhere to the dura and nerve roots 
(Figure 4.6).  In some cases, fibrosis was so severe that the vertebral canal and nerve 
roots were indistinguishable from the surrounding fibrotic tissue (Figure 4.7).  Fibrosis 
also occasionally extended to areas adjacent to those that had undergone laminectomy. 
Of the 25 rats in the normal saline group, 20 rats had grade 4, four had grade 3 
and one had grade 2 epidural fibrosis.  Rats treated with normal saline demonstrated 
significantly more fibrosis than control (nonsurgical) rats (p < 0.05). 
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Figure 4.5: Histology of nonsurgical control rat.  
Superficial epaxial muscles (SM), deep epaxial muscles (DM), neural elements (NE), 
first sacral vertebra posterior elements (S), ileosacral articulation (SI). Masson trichrome 
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Figure 4.6: Histology of normal saline treated rat following laminectomy.  
High grade (grade 3) epidural fibrosis at laminectomy site.  (A) Cephalad to the 
laminectomy; (B) At the laminectomy site; (C) Caudal to the laminectomy site. Masson 
trichrome stain technique, 20X magnification.   	  
A	   B	  
C	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Figure 4.7: Histology of rat having undergone laminectomy, severe fibrosis at 
laminectomy site.   
At laminectomy site (circled), neural elements are indistinguishable from fibrotic 
material. Masson trichrome technique, 20X magnification.  	  
4.4.4 Observations in alanyl-glutamine treated animals 
Similar to normal saline treated rats, alanyl-glutamine treated rats undergoing 
laminectomy demonstrated exuberant fibrosis in the epidural, deep and superficial epaxial 
layers (Figure 4.8).  
Of the 26 rats in the alanyl-glutamine treatment group, 20 rats had grade 4 and six 
had grade 3 epidural fibrosis.  The quality or maturity of the fibrotic material did not 
appear qualitatively different from that observed in the surgical control (normal saline) 
group.  When comparing rats treated with alanyl-glutamine (n=26) and normal saline 
control rats (n=25), there was no statistically significant difference in the grade of 
epidural fibrosis (p=0.83, Figure 4.9).  
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Figure 4.8: Histology of alanyl-glutamine treated rat following laminectomy.  
High grade (grade 3) epidural fibrosis at laminectomy site.  (A) Cephalad to the 
laminectomy; (B) At the laminectomy site; (C) Caudal to the laminectomy site. Masson 
trichrome technique, 20X magnification.   
 	  
A	   B	  
C	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Figure 4.9: Histological grade of epidural fibrosis in surgical control and alanyl-
glutamine treatment groups.  
When comparing rats treated with alanyl-glutamine (n=26) and normal saline control rats 
(n=25), there was no statistically significant difference in the grade of epidural fibrosis 
(p=0.83). 	  
Groups were also combined as subsets of ‘low grade’ (grade 1 and 2) and ‘high 
grade’ (grade 3 and 4) and compared.  When comparing rats treated with normal saline, 
there was no statistically significant difference between the low and high-grade subsets 
(p=0.89, Figure 4.10). 
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Figure 4.10: Histological grade of epidural fibrosis in "low grade" and "high grade" 
subsets.  
When comparing rats treated with normal saline, there was no statistically significant 
difference between the low and high-grade subsets (p=0.89). 	  
4.5 Intra- and inter-observer reliability of the grading scheme 
Based on 104 pairs of independent observations performed by two raters, the 
intra-rater reliability kappa value was 0.71 (p<0.001), 95% CI (0.60, 0.80).  The inter-
rater reliability kappa value was 0.62 (p<0.001), 95% CI (0.47, 0.77). 
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5. DISCUSSION 
5.1 Effectiveness of the rat laminectomy model for studying epidural fibrosis 
Due to availability, low cost and ease of care, the rat laminectomy model has been 
popular in studies investigating therapeutic interventions for epidural fibrosis.  All 
models have caveats, and for the rat laminectomy model, these are primarily anatomical 
concerns.  The small size of the animal, thin lamina, small epidural space and low set 
conus medullaris (the terminal end of the spinal cord) increase the technical challenge of 
surgical interventions on the spine116.  Nevertheless, the model continues to be 
successfully used in studies that employ histological techniques to evaluate potential 
therapeutic interventions240-243. 
The results of this study confirm the suitability of the rat laminectomy model for 
studying epidural fibrosis.  There was a learning curve associated with the operative 
procedure, with the first fifty percent of procedures taking significantly longer than the 
latter half.  However, the surgical procedure was performed with minimal postoperative 
complications, and without devastating neurologic sequelae.  When compared to rats that 
did not undergo surgery, rats that underwent surgical laminectomy demonstrated 
exuberant fibrotic proliferation in the epidural space.  The significant response seen 
would be suitable for testing potent antifibrotic agents.  It would be less suitable for 
testing less potent agents for which a small effect may be masked by the overall 
exuberant fibrotic response. 
5.2 Lack of efficacy of alanyl-glutamine 
Based on presumed efficacy of alanyl-glutamine in reducing peritoneal adhesions 
in a post-surgical rat model232, I had hypothesized a similar effect on reduction of 
epidural fibrosis following laminectomy.  Although the topical application of alanyl-
glutamine appeared safe with no observed systemic complications, there was no 
statistically significant difference in grade of epidural fibrosis in alanyl-glutamine treated 
rats compared to those treated with normal saline.  The results of this study suggest that 
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direct application of an alanyl-glutamine solution to the epidural space does not have any 
effect on reducing epidural fibrosis at a histological level.  
5.3 Possible explanations for lack of efficacy 
Lack of effect may be related to the environment, the model, potency of the agent, 
treatment dose and duration of exposure.  Each of these factors may be wholly 
responsible for or contribute to the lack of observed effect.   
5.3.1 Environmental differences 
The initial research that suggested a positive effect of alanyl-glutamine on 
reducing fibrosis utilized a rat peritoneal sepsis model232.  In this model, the 
inflammatory cascade was initiated as a result of a cecal ligation puncture, which resulted 
in both surgical trauma and bowel necrosis with fecal contamination and subsequent 
infection.  This is vastly different environment than that of the post-operative peridural 
region.  Additionally, the peritoneal model involves relatively little dissection and has 
negligible hematoma formation.  Given these differences, there may be alterations in the 
mechanisms of tissue repair and remodeling.   
In addition to the major differences in the models employed, there are 
dissimilarities in the macro- and microenvironments of the peritoneal cavity and the 
epidural space that may account for differences in observed effect of alanyl-glutamine.  
In contrast to the closed space of the peritoneal cavity, the treatment substance may leak 
from the surgical field into dissection planes and from the wound itself.  The peritoneum 
also has a greater absorptive surface, and the type and number of glutamine responsive 
cells may affect the efficiency of glutamine uptake and utilization.  
5.3.2 Sensitivity of the model 
It is possible that alanyl-glutamine may have an effect that is not detectable using 
this model.  The rats in this study demonstrated exuberant epidural fibrosis to the extent 
that it would be difficult to precisely quantify.  Models employing more sensitive 
techniques such as quantification of absolute numbers of fibroblasts or inflammatory 
cells though microscopy111 113 117 233 or immunohistochemistry38 113 124 may be more 
successful.  Based on discussions with a pathologist, we do not feel that either technique 
would be beneficial in our specimens due to the extent of fibrosis observed.  
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5.3.3 Delivery, dose and potency of the treatment substance 
Other factors to consider include the method of delivery, treatment dose and 
potency of the antifibrotic agent being studied.  While the extent of uptake and utilization 
of intravenously supplied alanyl-glutamine in the rat has been studied237 244, the extent of 
absorption via topical administration is unknown.  It is also unknown whether topical 
administration of alanyl-glutamine to the wound is the optimal delivery method for 
prevention of epidural fibrosis, and further study of intravenous administration may be 
warranted.   
The concentration of alanyl-glutamine used in this study approaches the 
maximum soluble concentration237, and the treatment dose was selected based on 
previous research232 235 236.  The minimum effective tissue concentration of alanyl-
glutamine required to exert an effect on fibrosis formation is unknown.  In order to 
further define this and optimal dose, in vitro studies utilizing inflammatory cells may be 
designed.  If there is no observed effect of alanyl-glutamine at maximal soluble 
concentration, multiple treatments or prolonged exposure may be considered. 
5.3.4 Duration of exposure 
The critical period of inflammatory cell trafficking into the healing wound is the 
early hours post-injury.  If alanyl-glutamine were to be effective, it would have to be 
present at minimally effective concentrations throughout this period.  While the half-life 
of alanyl-glutamine applied to the tissues is unknown, the half-life of intravenously 
supplied alanyl-glutamine is relatively short (range 5-16 minutes)237 245.  Even with the 
prolonged retention in the closed space of the peritoneal cavity, it is difficult to imagine 
that such a short exposure to alanyl-glutamine is able to exert any prolonged effect.  
Therefore, it would be desirable to increase duration of exposure with strategies to retain 
the solution in the surgical field and to control its release throughout the critical 
inflammatory period.  
5.4 Concern for reliability of the grading scheme 
The rating scale utilized in this study relies on subjective interpretation of 
histopathology.  It is therefore important to consider the validity of the scoring system by 
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assessing agreement of observers on subsequent re-observation (intra-rater reliability) 
and between different observers on the same observation (inter-rater reliability). 
In this study, the intra-rater reliability kappa value was 0.71 (p<0.001), 95% CI 
(0.60, 0.80).  The inter-rater reliability kappa value was 0.62 (p<0.001), 95% CI (0.47-
0.77). 
There are arbitrary guidelines in the literature classifying the degree of reliability.  
Landis and Koch suggested that kappa may be interpreted as: values <0.0 indicating no 
agreement, 0.0-0.20 as slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as 
substantial and 0.81-1.00 as almost perfect agreement246.  Applying these guidelines, the 
calculated kappa values suggest a “substantial” level of intra- and inter-rater agreement. 
However, concerns arise when considering the lower endpoint of the calculated 
confidence interval for kappa.  While still falling into “moderate” strength of agreement 
according to Landis and Koch, the values suggest a significant amount of inconsistency 
in individual interpretation, as well as across multiple data collectors.  Minimum 
acceptable levels of agreement in health research have not been established, but many 
authors suggest a minimum kappa value of 0.80247.  Improved definitions for each grade 
of epidural fibrosis may improve the intra-rater reliability.  The low inter-rater reliability 
may reflect the observations of a relatively inexperienced observer, and could be 
improved with observer training. 
5.5 Future directions 
 Epidural fibrosis after spinal surgery is inevitable.  The formation of post-surgical 
fibrosis is linked to the inflammatory cascade that occurs after injury, and the key to its 
prevention lies in successful modulation of this pathway. 
 An understanding of the basic mechanisms by which glutamine acts to reduce 
peritoneal adhesions is lacking.  Resources may be better utilized to define this 
mechanism, and further studies can be designed to exploit those specific mechanisms.  
Data outlining the topical absorption and in vivo tissue half-life of alanyl-glutamine 
would also be useful to appropriately target delivery of maximal concentrations of alanyl-
glutamine.  Future research may also explore controlled elution of the treatment 
substance in an animal model.  Only after repeated positive results in controlled animal 
studies can any potential treatment be considered for human trials. 
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 Currently, there is no treatment which has been consistently proven effective in 
human trials and which is in routine clinical use to prevent epidural fibrosis following 
spine surgery.    With no effective therapy available, prevention remains the goal, and 
surgeons should aim for minimal tissue disruption with meticulous hemostasis. 
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